Veradermics reports FY 2025 results and post-IPO cash runway through 2029

Veradermics (NYSE:MANE), a late-clinical stage biopharmaceutical firm specializing in aesthetic and dermatological therapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

The company reported a net loss of $70 million for the full year 2025, compared to $26.5 million in 2024.

For the fourth quarter alone, the net loss reached $21.8 million.

This expansion in net loss was driven primarily by a surge in research and development (R&D) expenses, which totaled $62.1 million for the year—a nearly 166% increase over the previous year's $23.3 million.

Management attributed the higher spend to the accelerated clinical development of VDPHL01, as well as a strategic increase in R&D headcount to support late-stage trials.

General and administrative (G&A) expenses also saw an uptick, rising to $10.3 million for the year compared to $3.5 million in 2024.

The increase was largely tied to personnel-related costs, stock-based compensation, and professional fees associated with the company's transition toward the public markets.

Despite the widened losses, Veradermics enters 2026 with a significantly fortified balance sheet.

While the company ended 2025 with $141.9 million in cash and marketable securities, it successfully completed an initial public offering (IPO) subsequent to year-end.

The offering raised approximately $294.8 million in gross proceeds.

Combined with existing reserves, Veradermics now projects its cash position will be sufficient to support current operating plans and clinical milestones into 2029.